Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate

Journal of Virology

Volumn 77, Issue 3, 2003, Pages 2276-2281

  Faulkner, Neil E ^a   Lane, Brian R ^a   Bock, Paul J ^a   Markovitz, David M ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOPROTEIN PHOSPHATASE 2A;

ARTICLE; CELL GROWTH; ENHANCER REGION; ENZYME LOCALIZATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS ACTIVATION; VIRUS REPLICATION;

ALKENES; HIV-1; HUMANS; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C; PYRONES; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; VIRUS ACTIVATION;

EID: 0037302323     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.3.2276-2281.2003     Document Type: Article

References (41)

1. Aydin, H. H., N. Selvi, G. Saydam, M. Tobu, S. Uzunoglu, R. Uslu, F. Buyukkececi, and S. B. Omay. 2000. Up-regulation of serine/threonine protein phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukaemic HL-60 cells. Clin. Lab. Haematol. 22: 271-274.
2. Baharians, Z., and A. H. Schonthal. 1998. Autoregulation of protein phosphatase type 2A expression. J. Biol. Chem. 273:19019-19024.
3. Baldari, C. T., G. Macchia, A. Massone, and J. L. Telford. 1992. p21ras contributes to HIV-1 activation in T-cells. FEBS Lett. 304:261-264.
4. Bell, B., and L. Sadowski. 1996. Ras-responsiveness of the HIV-1 LTR requires RBF-1 and RBF-2 binding sites. Oncogene 13:2687-2697.
5. Chang, Y. Y., S. J. Kim, T. K. Park, S. S. Kang, M. J. Ha, J. F. Mushinski, and J. S. Chun. 1998. Modulation of MAP kinase signaling and growth characteristics by the overexpression of protein kinase C in NIH3T3 cells. Biochem. Mol. Biol. Int. 45:1139-1148.
6. Chen, P., E. Flory, A. Avots, B. W. Jordan, F. Kirchhoff, S. Ludwig, and U. R. Rapp. 2000. Transactivation of naturally occurring HIV-1 long terminal repeats by the JNK signaling pathway. The most frequent naturally occurring length polymorphism sequence introduces a novel binding site for AP-1 factors. J. Biol. Chem. 275:20382-20390.
7. Chun, R. F., O. J. Semmes, C. Neuveut, and K. T. Jeang. 1998. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J. Virol. 72:2615-2629.
8. Chung, H., and D. L. Brautigan. 1999. Protein phosphatase 2A suppresses MAP kinase signalling and ectopic protein expression. Cell. Signal. 11:575-580.
9. Crowe, S. 1995. Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Aust. N. Z. J. Med. 25:777-783.
10. de Jong, R. S., E. G. de Vries, S. Meijer, P. E. de Jong, and N. H. Mulder. 1998. Renal toxicity of the anticancer drug fostriecin. Cancer Chemother. Pharmacol. 42:160-164.
11. de Jong, R. S., E. G. de Vries, and N. H. Mulder. 1997. Fostriecin: a review of the preclinical data. Anticancer Drugs 8:413-418.
12. de Jong, R. S., N. H. Mulder, D. R. Ugles, D. T. Sleijfer, F. J. Hoppener, H. J. Groen, P. H. Willemse, W. T. van der Graaf, and E. G. de Vries. 1999. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Br. J. Cancer 79:882-887.
13. de Jong, S., J. G. Zijlstra, N. H. Mulder, and E. G. de Vries. 1991. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother. Pharmacol. 28:461-464.
14. Faulkner, N. E., J. M. Hilfinger, and D. M. Markovitz. 2001. Protein phosphatase 2A (PP2A) activates the HIV-2 promoter through enhancer elements that include the pets site. J. Biol. Chem. 276:25804-25812.
15. Flory, E., C. K. Weber, P. Chen, A. Hoffmeyer, C. Jassoy, and U. R. Rapp. 1998. Plasma membrane-targeted Raf kinase activates NF-κB and human immunodeficiency virus type 1 replication in T lymphocytes. J. Virol. 72: 2788-2794.
16. Folgueira, L, A. Algeciras, W. S. MacMorran, G. D. Bren, and C. V. Paya. 1996. The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and participates in the activation of NF-κB. J. Virol. 70:2332-2338.
17. Garcia, A., S. Cereghini, and E. Sontag. 2000. Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters. J. Biol. Chem. 275:9385-9389.
18. Gendelman, H. E., and M. S. Meltzer. 1989. Mononuclear phagocytes and the human immunodeficiency virus. Curr. Opin. Immunol. 2:414-419.
19. Hannibal, M. C., D. M. Markovitz, N. Clark, and G. J. Nabel. 1993. Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals. J. Virol. 67:5035-5040.
20. Hastie, C. J., and P. T. Cohen. 1998. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters. FEBS Lett. 431:357-361.
21. Kagnoff, M. F., and K. A. Roebuck. 1999. Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. J Infect. Dis. 179(Suppl. 3):S444-S447.
22. Lembo, D., A. Angeretti, M. Gamboli, R. Cavallo, and S. Landolfo. 1995. Modulation of HIV-LTR activity by ras oncogenes. New Microbiol. 18:111-116.
23. Marquardt, B., D. Frith, and S. Stabel. 1994. Signalling from TPA to MAP kinase requires protein kinase C, raf and MEK: reconstitution of the signalling pathway in vitro. Oncogene 9:3213-3218.
24. Morita, K., M. Nishikawa, K. Kobayashi, K. Deguchi, M. Ito, T. Nakano, H. Shima, M. Nagao, T. Kuno, C. Tanaka, et al. 1992. Augmentation of retinoic acid-induced granulocytic differentiation in HL-60 leukemia cells by serine/threonine protein phosphatase inhibitors. FEBS Lett. 314:340-344.
25. Ogris, E., X. Du, K. C. Nelson, E. K. Mak, X. X. Yu, W. S. Lane, and D. C. Pallas. 1999. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J. Biol. Chem. 274:14382-14391.
26. c-src. J. Virol. 73: 7390-7398.
27. Pereira, L. A., K. Bentley, A. Peeters, M. J. Churchill, and N. J. Deacon. 2000. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 28:663-668.
28. Potts, B. 1990. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
29. Qiu, Z. H., and C. C. Leslie. 1994. Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A2. J. Biol. Chem. 269:19480-19487.
30. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R. S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retrovir. 3:57-69.
31. Ricciarelli, R., and A. Azzi. 1998. Regulation of recombinant PKC alpha activity by protein phosphatase 1 and protein phosphatase 2A. Arch. Biochem. Biophys. 355:197-200.
32. Roberge, M., C. Tudan, S. M. Hung, K. W. Harder, F. R. Jirik, and H. Anderson. 1994. Antitumor drug fostriecin inhibits the mitotic entry check-point and protein phosphatases 1 and 2A. Cancer Res. 54:6115-6121.
33. Rosen, C. A., J. G. Sodroski, and W. A. Haseltine. 1985. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
34. Ruediger, R., N. Brewis, K. Ohst, and G. Walter. 1997. Increasing the ratio of PP2A core enzyme to holoenzyme inhibits Tat-stimulated HIV-1 transcription and virus production. Virology 238:432-443.
35. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
36. Schonthal, A. H. 1998. Role of PP2A in intracellular signal transduction pathways. Front. Biosci. 3:D1262-D1273.
37. Seligmann, M. 1990. Immunological features of human immunodeficiency virus disease. Bailliere's Clin. Haematol. 3:37-63.
38. Thevenin, C., S. J. Kim, P. Rieckmann, H. Fujiki, M. A. Norcross, M. B. Sporn, A. S. Fauci, and J. H. Kehrl. 1990. Induction of nuclear factor-kappa B and the human immunodeficiency virus long terminal repeat by okadaic acid, a specific inhibitor of phosphatases 1 and 2A. New Biol. 2:793-800.
39. Vlach, J., A. Garcia, J. M. Jacque, M. S. Rodrigues, S. Michelson, and J. L. Virelizier. 1995. Induction of Sp1 phosphorylation and NF-κB-independent HIV promoter domain activity in T lymphocytes stimulated by okadaic acid. Virology 208:753-761.
40. Walsh, A. H., A. Cheng, and R. E. Honkanen. 1997. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett. 416:230-234.
41. Weinbrenner, C., C. P. Baines, G. S. Liu, S. C. Armstrong, C. E. Ganote, A. H. Walsh, R. E. Honkanen, M. V. Cohen, and J. M. Downey. 1998. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation 98:899-905.